Speaker illustration

Doctor Manan Pareek

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)

Member of:

European Society of Cardiology
EAPCI

Dr. Manan Pareek is an MD, PhD, FAHA, FESC, currently working as a resident in internal medicine. He has co-supervised 5 masters theses and co-mentored 5 PhD-students. He has almost 15 years of teaching experience. Dr. Pareek has been a volunteer member of the Danish Society of Cardiology since 2014 where he has authored or co-authored 5 guidelines and been on the endorsement committees for two ESC guidelines (dual antiplatelet therapy and hypertension). He is also a member of the International Society of Cardiovascular Disease Epidemiology and Prevention, given his particular interest in these research areas. He has worked with hyperglycemia, insulin resistance, hypertension, biomarkers, and prediction of diabetes, cardiovascular disease, and mortality. Finally, Dr. Pareek serves as a peer reviewer for >40 journals and has reviewed abstracts for the American Heart Association and ESC since 2018. He has authored or co-authored >180 publications (>95 peer-reviewed articles).

Greater event rates in high-risk patients with a history of heart disease: from the Systolic Blood Pressure Intervention Trial (SPRINT)

Event: ESC Congress 2021 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Hypertension e-posters

Thumbnail

Marital status, cardiovascular events, and intensive blood pressure lowering among men and women in the Systolic Blood Pressure Intervention Trial

Event: ESC Congress 2021 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Hypertension e-posters

Thumbnail

YNHHS-COVID-19 - Cardiac Complications Registry

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology

Session: COVID and Cardiovascular Disease

Thumbnail

Serial changes in high-sensitivity troponin I levels indicate poorer prognosis in patients with suspected acute coronary syndrome who fail to reach a level greater than the 99th percentile

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Acute Coronary Syndromes ePosters

Thumbnail

Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: The Systolic Blood Pressure Intervention Trial (SPRINT)

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Hypertension ePosters

Thumbnail

The ESC algorithm for serial high-sensitivity troponin T changes and long-term outcomes in patients with suspected acute coronary syndrome

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Acute Coronary Syndromes ePosters

Thumbnail

2018 ESC/ESH guideline-recommended age categories and intensive blood pressure management in high-risk adults: insights from SPRINT

Event: ESC CONGRESS 2019

Topic: Pharmacotherapy

Session: Hypertension: epidemiology, targets and comorbidities

Thumbnail

Renal function and intensive blood pressure lowering in high-risk adults without diabetes: insights from the Systolic Blood Pressure Intervention Trial (SPRINT)

Event: ESC CONGRESS 2019

Topic: Pharmacotherapy

Session: Blood pressure targets in high risk patients: challenges and opportunities

Thumbnail

10-year outcomes from a randomized comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study

Event: ESC Congress 2018

Topic: Stents

Session: Outcome of coronary stenting up to 10 years

Thumbnail

Body mass index and intensive blood pressure management in high-risk adults: insights from the systolic blood pressure intervention trial SPRINT)

Event: ESC Congress 2018

Topic: Epidemiology, Prognosis, Outcome

Session: Refining risk assessment in hypertension

Thumbnail

This platform is supported by

logo Novo Nordisk